Latest insights

The latest news, blog posts, and podcasts featuring Angiex

Press releases

07 August 2024

Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101

Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors

Read more

02 November 2023

22 September 2023

In the media

11 October 2024

How to Build Your Biotech Company in 2024 (According to Founders)

Angiex was featured as one of a select few companies in Labiotech’s article on building successful biotech startups. CEO Paul Jaminet shared insights on the advantages of Cambridge’s biotech ecosystem.

Read more

07 October 2024

North American Biotech Innovation: Who and Where?

Angiex is featured in Drug Discovery World as a leading North American biotech innovator. CEO Paul Jaminet discusses the critical role of Cambridge’s infrastructure in the company’s early success and its development of TM4SF1-directed ADCs.

Read more

15 August 2024

Abzena Supplies Clinical Trial Material for Angiex's Phase I Study Of AGX101, A First-In-Class TM4SF1-Directed ADC

Angiex doses the first patient in its Phase 1 trial of a novel antibody-drug conjugate (ADC) therapy targeting blood vessels in tumors, marking a significant milestone in cancer treatment development

Read more

Founder's blog

25 November 2024

Welcome to the Angiex Founder's Blog

Welcome to the Angiex Founder's Blog

Read more

Podcasts

31 October 2024

An inside look at Angiex’s development of AGX101

Watch Angiex CEO Dr. Paul Jaminet and founder Dr. Harold Dvorak, a leading authority on angiogenesis, present at a Force Family Office webinar. This engaging session offers an inside look at Angiex’s development of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to target both tumor cells and the blood vessels that feed them

Read more

20 September 2024

Angiex CEO presents on AGX101’s groundbreaking mechanism of action

Join Angiex CEO Dr. Paul Jaminet as he presents at the MedInvest 2024 October Meeting, offering a comprehensive overview of AGX101, the company’s first-in-class TM4SF1-directed antibody-drug conjugate (ADC).

Read more

08 September 2024

Don Davis’s Life Science Success podcast

Angiex's CEO, Paul Jaminet, discusses the company’s innovative approach to cancer therapies, including their focus on TM4SF1-targeted ADCs, and the challenges and opportunities in advancing breakthrough treatments.

Read more

Scientific communications

13 January 2025

Angiex presents preclinical data at ASCO GI Cancers Symposium, San Francisco

More details and link to download poster coming soon...

Read more

17 November 2024

Angiex presents preclinical data at AACR Special Conference in Cancer Research

Taking place November 17-20, 2024 in Boston, Massachusetts, will feature a poster presentation by Angiex, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial.”

Read more

07 May 2024

Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101

Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101

Read more

Contact us

Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...